Levels as Risk Predictors of Bisphosphonate Related Osteonecrosis of the Jaw.

SEIJO M; PICARDO S; ZENI SN; RODRIGUEZ GENTA S; REY E

Global J Endocrinol Metab

Crimson Publishedn LLC

Lugar: New York; Año: 2021 vol. 3

2637-8019

Bisphosphonates (BPs) are anticatabolic drugs of choice for treating bone diseases, including bone metastases. Maxillary osteonecrosis associated to chronic treatment with BPs (BRONJ) is one of the possible complications. Crosslaps (CTX) could be used as a biochemical marker for risk of developing ONJ. Vitamin D (VD) may be involved in this pathology. Nutritional status of VD and CTX levels were evaluated and compared in women BPs-treated: group I (n = 28) without BRONJ and group II (n = 58) with BRONJ. Group II were older and has more treatment time (p=0.0000036). No differences were found in calcemia, phosphatemia and CTX levels; FAO was significantly higher and 25OHD significantly lower in group II (p=0.040) and p=0.035, respectively). Subject?s percentage having CTX between 100 and 149 mg / mL was similar. Group I had no VD deficiency but 18% of group II presented it. No different percentage of VD insufficiency or sufficiency (50% group I and 40% group II) was observed. Conclusion: CTX levels did not shown predictive value to detect risk of developing of BRONJ. The high percentage of women with hypovitaminosis D suffering from BRONJ suggests the importance of determining this physiological state, due to the possible relationship with the development of ONJ.